Equities research analysts expect TG Therapeutics Inc (NASDAQ:TGTX) to report earnings of ($0.46) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for TG Therapeutics’ earnings, with estimates ranging from ($0.49) to ($0.43). TG Therapeutics posted earnings of ($0.48) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 4.2%. The firm is expected to issue its next quarterly earnings report on Friday, March 9th.
On average, analysts expect that TG Therapeutics will report full year earnings of ($1.87) per share for the current fiscal year, with EPS estimates ranging from ($1.94) to ($1.75). For the next financial year, analysts anticipate that the company will post earnings of ($1.69) per share, with EPS estimates ranging from ($1.96) to ($1.08). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow TG Therapeutics.
TGTX has been the topic of a number of recent research reports. B. Riley initiated coverage on shares of TG Therapeutics in a report on Friday, December 1st. They issued a “buy” rating and a $21.50 target price on the stock. Zacks Investment Research lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. HC Wainwright restated a “buy” rating and issued a $33.00 target price on shares of TG Therapeutics in a report on Monday, January 8th. BidaskClub lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 23rd. Finally, Raymond James Financial restated a “buy” rating on shares of TG Therapeutics in a report on Tuesday, December 12th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $25.44.
TG Therapeutics (NASDAQ:TGTX) traded up $0.05 during trading hours on Wednesday, reaching $14.05. 962,946 shares of the company’s stock were exchanged, compared to its average volume of 1,860,000. The stock has a market cap of $996.21, a price-to-earnings ratio of -7.28 and a beta of 1.67. TG Therapeutics has a 52 week low of $5.35 and a 52 week high of $15.35.
In other news, CFO Sean A. Power sold 32,006 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total transaction of $272,051.00. Following the transaction, the chief financial officer now directly owns 517,464 shares in the company, valued at approximately $4,398,444. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 16.70% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Segall Bryant & Hamill LLC lifted its holdings in shares of TG Therapeutics by 14.0% during the 4th quarter. Segall Bryant & Hamill LLC now owns 61,092 shares of the biopharmaceutical company’s stock worth $501,000 after acquiring an additional 7,500 shares during the period. MetLife Investment Advisors LLC purchased a new position in shares of TG Therapeutics during the 4th quarter worth about $172,000. BB&T Securities LLC lifted its holdings in shares of TG Therapeutics by 153.4% during the 4th quarter. BB&T Securities LLC now owns 33,700 shares of the biopharmaceutical company’s stock worth $276,000 after acquiring an additional 20,400 shares during the period. Nexthera Capital LP purchased a new position in shares of TG Therapeutics during the 4th quarter worth about $246,000. Finally, Raymond James & Associates lifted its holdings in shares of TG Therapeutics by 137.2% during the 4th quarter. Raymond James & Associates now owns 211,595 shares of the biopharmaceutical company’s stock worth $1,735,000 after acquiring an additional 122,400 shares during the period. Institutional investors and hedge funds own 46.90% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “TG Therapeutics Inc (TGTX) Expected to Post Earnings of -$0.46 Per Share” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://transcriptdaily.com/2018/02/24/tg-therapeutics-inc-tgtx-expected-to-post-earnings-of-0-46-per-share.html.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.